Viridian Therapeutics, Inc.\DE (VRDN) EBIT (2013 - 2026)

Viridian Therapeutics, Inc.\DE's EBIT history runs 14 years deep, the most recent figure standing at -$116.2 million for Q1 2026.

• On a quarterly basis, EBIT fell 23.76% year-over-year to -$116.2 million in Q1 2026; TTM through Mar 2026 was -$385.7 million, a 14.45% decrease from a year earlier, with the FY2025 full-year figure at -$363.4 million, down 21.52% from the prior year.
• EBIT grew to -$116.2 million in Q1 2026 per VRDN's latest filing, from -$122.7 million in the prior quarter.
• Across five years, EBIT topped out at -$25.9 million in Q1 2022 and bottomed at -$122.7 million in Q4 2025.
• The 5-year median for EBIT is -$71.5 million (2023), against an average of -$68.7 million.
• Across the five-year window, EBIT sank 179.94% in 2023 and surged 52.07% in 2025, its largest moves.
• Year by year, EBIT stood at -$49.1 million in 2022, then slumped by 45.68% to -$71.5 million in 2023, then dropped by 22.38% to -$87.5 million in 2024, then sank by 40.33% to -$122.7 million in 2025, then grew by 5.36% to -$116.2 million in 2026.
• Per Business Quant, the three latest VRDN EBIT figures stand at -$116.2 million (Q1 2026), -$122.7 million (Q4 2025), and -$40.0 million (Q3 2025).